Mind Medicine (MindMed) Inc. (FRA:MMQ)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.17B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -143.27M |
| Shares Out | n/a |
| EPS (ttm) | -1.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33 |
| Average Volume | 122 |
| Open | 11.49 |
| Previous Close | 11.65 |
| Day's Range | 11.49 - 12.36 |
| 52-Week Range | 4.29 - 12.36 |
| Beta | n/a |
| RSI | 66.84 |
| Earnings Date | Mar 5, 2026 |
About Mind Medicine (MindMed)
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. [Read more]
News
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026?
MNMD has surged 101% in six months with MM120 advancing in phase III for GAD and MDD. Pivotal readouts are slated for 2026.
Jones Trading Initiates Coverage on Mind Medicine (MNMD) with 'Buy' Rating | MNMD Stock News
Jones Trading Initiates Coverage on Mind Medicine (MNMD) with 'Buy' Rating | MNMD Stock News
MindMed a new buy at Jones on promise of psychedelics for mental illnesses
MindMed (MNMD) is set for growth in psychedelic neuropsychiatry with strong clinical data and major stock upside potential, according to Jones. Read more here.
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors
MindMed Announces New Employee Inducement Grant
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
MindMed Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
MNMD: Canaccord Genuity Raises Price Target to $25, Maintains Buy Rating | MNMD Stock News
MNMD: Canaccord Genuity Raises Price Target to $25, Maintains Buy Rating | MNMD Stock News
RBC Capital Lowers Price Target for MNMD While Maintaining Outperform Rating | MNMD Stock News
RBC Capital Lowers Price Target for MNMD While Maintaining Outperform Rating | MNMD Stock News
Mind Medicine Inc (MNMD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ...
Mind Medicine Inc (MNMD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges
Q3 2025 Mind Medicine (MindMed) Inc Earnings Call Transcript
Q3 2025 Mind Medicine (MindMed) Inc Earnings Call Transcript
MindMed (MNMD) Strengthens Financial Position with $259M Offering
MindMed (MNMD) Strengthens Financial Position with $259M Offering
Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript
MindMed (MNMD) Q3 2025 Earnings Call Transcript
MindMed (MNMD) Q3 2025 Earnings Call Transcript
MindMed (MNMD) Secures Strong Financial Position for Key Developments in 2026
MindMed (MNMD) Secures Strong Financial Position for Key Developments in 2026
MindMed Reports Q3 2025 Financial Results and Business Updates
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...
MindMed to Participate in Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
MindMed Announces New Employee Inducement Grant
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
MindMed to Report Q3 2025 Financial Results on November 6, 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy
Mind Medicine (MNMD) is advancing its lead drug MM120 through Phase 3 trials for anxiety and depression, positioning for long-term upside. MNMD's strong cash reserves, disciplined spending, and extend...
Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression
Needham initiated coverage on Mind Medicine Inc. (NASDAQ:MNMD), or MindMed, on Monday. The late-stage clinical biopharmaceutical company is developing novel product candidates to treat brain health di...